Global aesthetic dermatology firm Sinclair Pharma is forecast to deliver a modest profit. "As previously guided, the group expects to deliver a modest Ebitda profit for the year as a whole," the company said. The London-based company saw revenue rise as expected, with sales for the year to December rising by 20% to £45.3m ($62.3m) or by 14% on a constant currency basis. However, its chief executive, Dr David Sinclair, said that while he was pleased with sales, it would not be enough to offset the impact of Brexit and other factors.
Global aesthetic dermatology firm Sinclair Pharma is forecast to deliver a modest profit. The London-based company saw revenue rise as expected, with sales for the year to December rising by 20% to £45.3m ($62.3m) or by 14% on a constant currency basis. However, its chief executive, Dr David Sinclair, said that while he was pleased with sales, it would not be enough to offset the impact of Brexit and other factors.